1. Home
  2. SABS vs OPRT Comparison

SABS vs OPRT Comparison

Compare SABS & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.85

Market Cap

288.8M

Sector

Health Care

ML Signal

N/A

Logo Oportun Financial Corporation

OPRT

Oportun Financial Corporation

HOLD

Current Price

$5.57

Market Cap

238.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SABS
OPRT
Founded
2014
2005
Country
United States
United States
Employees
86
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
288.8M
238.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SABS
OPRT
Price
$3.85
$5.57
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$10.75
$7.00
AVG Volume (30 Days)
996.7K
365.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
127.18
EPS
N/A
0.05
Revenue
N/A
$956,685,000.00
Revenue This Year
N/A
$32.79
Revenue Next Year
N/A
$4.47
P/E Ratio
N/A
$108.50
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$4.03
52 Week High
$6.60
$7.73

Technical Indicators

Market Signals
Indicator
SABS
OPRT
Relative Strength Index (RSI) 52.16 53.45
Support Level $3.54 $5.51
Resistance Level $4.11 $5.68
Average True Range (ATR) 0.35 0.28
MACD 0.01 -0.03
Stochastic Oscillator 37.74 54.65

Price Performance

Historical Comparison
SABS
OPRT

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: